Mylan (MYL) Unit Gets Health Canada Approval for Generic Tracleer Tabs
Tweet Send to a FriendGet Alerts MYL Hot Sheet
Down)
Trade MYL Now!
Mylan Inc. (Nasdaq: MYL) reports that its Canadian subsidiary, Mylan Pharmaceuticals ULC, has received approval from Health Canada for Mylan-Bosentan Tablets, 62.5 mg and 125 mg. Mylan-Bosentan is the generic version of Actelion Pharmaceuticals Ltd.'s Tracleer, used for the treatment of pulmonary arterial hypertension(1). According to IMS Health, Bosentan Tablets had Canadian sales of approximately $37.8 million(2) for the 12 months ending March 31, 2012.
Currently, Mylan Canada has 38 product applications pending Health Canada approval. These 38 products represent $2.6 billion in annual sales for the 12 months ending March 31, 2012, according to IMS Health.
In Canada, generic drugs cost consumers an average of 60% less than their brand name counterparts.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Currently, Mylan Canada has 38 product applications pending Health Canada approval. These 38 products represent $2.6 billion in annual sales for the 12 months ending March 31, 2012, according to IMS Health.
In Canada, generic drugs cost consumers an average of 60% less than their brand name counterparts.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Depomed (DEPO) Reports Submission of ANDA for Generic Zipsor
- MediciNova (MNOV) Pops Higher Following Presentation of Significant MN-166 Phase Ib Data
- Actavis (ACT), Kissei Pharma Sue Sandoz, Hetero Over Rapaflo Patent
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
